Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02770365 · ClinicalTrials.gov registry record · Phase 3
Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy
A Phase 3 study of Atrophy, sponsored by Padagis.
- Completed
- Registry status
- Phase 3
- Development phase
- 695
- Enrollment target
- 1
- Study location
NCT02770365 is a Phase 3 study of Atrophy that has completed, run by Padagis. The registered enrollment target is 695 participants, above the 106-participant average among 5 other Atrophy trials with a reported enrollment target (556% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02770365, a Phase 3 study of Atrophy, has completed, sponsored by Padagis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 695 participants
- Enrollment target
- 1
- Study location
Study Summary
To compare safety and efficacy of Perrigo's drug product compared to an FDA approved drug product in the treatment of vulvar and vaginal atrophy.
Conditions Studied
Interventions
- DRUG estrace cream (Perrigo)
- DRUG estrace cream (Reference)
- DRUG Placebo cream
Study Locations (1)
Florida
- Comprehensive Clinical Trials, LLC - West Palm Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 695 participants |
| Start Date | 2016-05 |
| Est. Completion | 2016-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02770365
The ClinicalTrials.gov registry entry for NCT02770365 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 695 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 106-participant average among 5 other Atrophy trials with a reported enrollment target (556% higher). The listed sponsor is Padagis, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrophy appearing as the primary indexed condition, and to 3 interventions - of which estrace cream (Perrigo) is the first listed.
NCT02770365 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02770365 about?
NCT02770365 is a clinical study titled "Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy". To compare safety and efficacy of Perrigo's drug product compared to an FDA approved drug product in the treatment of vulvar and vaginal atrophy.
What is the current status of trial NCT02770365?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 695 participants. The study started on 2016-05. Estimated completion is 2016-11.
What conditions does trial NCT02770365 study?
This clinical trial studies the following conditions: Atrophy.
What interventions are being tested in trial NCT02770365?
The interventions under investigation include: estrace cream (Perrigo) (DRUG), estrace cream (Reference) (DRUG), Placebo cream (DRUG).
Who is sponsoring clinical trial NCT02770365?
This trial is sponsored by Padagis, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02770365 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
COMPLETED · Phase 3
-
Influence of β-hydroxy β-methyl Butyrate (HMB)Supplementation on Post-operative Muscle Mass and Function in Female Athletes
RECRUITING · Phase 2
-
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
COMPLETED · Phase 2
-
Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.